Frankfurt
03.04.25
08:15 Uhr
25,750 Euro
-0,900
-3,38 %
-3,38 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | XVIVO Perfusion AB: Annual Report 2024 | 176 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
| 20.03. | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 226 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen | |
| 28.01. | XVIVO Perfusion AB: Year-End Report 2024 | 198 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), corresponding... ► Artikel lesen | |
| XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
| 13.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2024 | 296 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen | |
| 26.11.24 | XVIVO Perfusion AB: Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology | 366 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in the US clinical trial "PRESERVE:... ► Artikel lesen | |
| 14.11.24 | XVIVO Perfusion AB: XVIVO Perfusion Appoints Lena Hagman as Deputy CEO | 240 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / November 14, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has today appointed Lena Hagman... ► Artikel lesen | |
| 24.10.24 | XVIVO Perfusion AB: Interim Report January-September 2024 | 292 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2024 (July 1 - September 30)• Net sales amounted to SEK 198.5 million (146.6), corresponding... ► Artikel lesen | |
| 10.10.24 | XVIVO Perfusion AB: Conference Call on Interim Report | 242 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / October 10, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report January-September... ► Artikel lesen | |
| 19.09.24 | XVIVO Perfusion AB: XVIVO to Acquire a Unique Communication Platform for the Transplant Process | 824 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / September 19, 2024 / Today, XVIVO Perfusion AB (publ) (STO:XVIVO)(LSE:0RKL)(FRA:3XV) ("XVIVO" or "the Company") has entered into an agreement to acquire the transplant... ► Artikel lesen | |
| 06.09.24 | Nomination Committee of XVIVO Perfusion AB | 398 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / September 6, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following members have been appointed to XVIVO Perfusion's nomination committee for the 2025... ► Artikel lesen | |
| 16.08.24 | XVIVO Perfusion AB: Results From European Randomized Controlled Study Using XVIVO's Heart Technology Published in The Lancet | 560 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / August 16, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, the results of the European randomized controlled clinical trial investigating the use of... ► Artikel lesen | |
| 12.07.24 | XVIVO Perfusion AB: Interim Report January - June 2024 | 390 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / July 12, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Second quarter 2024 (Apr 1 - Jun 30) • Net sales amounted to SEK 210.3 million (154.6), corresponding... ► Artikel lesen | |
| 25.06.24 | XVIVO Perfusion AB: Conference call on Interim Report | 246 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / June 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report April-June... ► Artikel lesen | |
| 25.04.24 | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 333 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / April 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion AB... ► Artikel lesen | |
| 24.04.24 | XVIVO Perfusion AB: Interim Report January-March 2024 | 377 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2024 (Jan 1 - Mar 31)• Net sales amounted to SEK 186.0 million (140.6), corresponding... ► Artikel lesen | |
| 11.04.24 | XVIVO Perfusion AB: Results from XVIVO's Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague | 448 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / April 11, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech... ► Artikel lesen | |
| 08.04.24 | XVIVO Perfusion AB: Conference call on Interim Report | 287 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / April 8, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report January-March... ► Artikel lesen | |
| 04.04.24 | XVIVO Perfusion AB: Annual Report 2023 | 661 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / April 4, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2023. The Annual Report is attached to... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 450,00 | -3,75 % | What the Options Market Tells Us About Intuitive Surgical | ||
| RHOEN-KLINIKUM | 13,800 | +2,22 % | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft: RHÖN-KLINIKUM AG schließt Geschäftsjahr erneut erfolgreich ab - Veränderungen im Vorstand / CEO Prof. Kaltenbach scheidet planmäßig aus dem Vorstand aus | EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Schlagwort(e): Jahresbericht/Jahresergebnis
RHÖN-KLINIKUM AG schließt Geschäftsjahr erneut erfolgreich ab - Veränderungen im Vorstand... ► Artikel lesen | |
| BICO GROUP | 2,746 | -4,78 % | Bico Group Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| HIMS & HERS HEALTH | 25,430 | -11,55 % | DAX in Wartestellung vor Trump-Zöllen - Thyssen, LVMH, CoreWeave, Hims & Hers, Ralph Lauren, Tesla | Der DAX hat gestern kräftig zugelegt und den Handelstag bei 22.539 Punkten beendet. Die Vorgaben aus Übersee sind größtenteils positiv. Allerdings richtet sich die Aufmerksamkeit immer mehr auf die... ► Artikel lesen | |
| M1 KLINIKEN | 15,400 | -3,75 % | M1 Kliniken Aktie: Ein unerwarteter Segen! | Die M1 Kliniken AG konnte im Geschäftsjahr 2024 ihre Umsatz- und Gewinnzahlen deutlich steigern, während der Aktienkurs aktuell bei 14,70 Euro und damit rund 33,5 Prozent unter seinem Jahreshoch notiert.... ► Artikel lesen | |
| BAXTER | 28,465 | -8,18 % | Baxter Aktie: Entwicklung auf gleichem Niveau | Die Baxter International Aktie verzeichnete in der vergangenen Woche eine moderate Erholung von 1,35 Prozent und schloss am Freitag bei 31,08 Euro, was einem leichten Tagesverlust von 0,48 Prozent entspricht.... ► Artikel lesen | |
| LIFEWARD | 1,570 | -6,55 % | Lifeward Ltd.: FDA Issues Clearance for ReWalk 7 Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| JD HEALTH | 3,800 | -5,94 % | JD HEALTH (06618): GRANT OF SHARE AWARDS AND UPDATE ON PREVIOUS SHARE AWARD GRANTS | ||
| COOPER COMPANIES | 71,50 | -4,48 % | COOPER COMPANIES, INC. - 8-K, Current Report | ||
| SURGICAL SCIENCE SWEDEN | 11,040 | -6,28 % | Surgical Science Sweden AB: Year-end report 2024: Strong end to the year | FOURTH QUARTER 2024 (OCT - DEC)Net sales amounted to SEK 251.5 (227.3) million, an increase of 11 percent compared with the corresponding period in the preceding year.License revenue amounted to SEK... ► Artikel lesen | |
| COMMUNITY HEALTH SYSTEMS | 2,320 | -1,69 % | COMMUNITY HEALTH SYSTEMS INC - 8-K, Current Report | ||
| ONWARD MEDICAL | 4,100 | -3,76 % | ONWARD Medical NV: ONWARD Medical Reports Full Year 2024 Financial and Operating Results and Shares 2025 Year-to-Date Highlights | Received FDA authorization and recorded first commercial sales of ARC-EX System
Secured strategic investment from Ottobock and extended cash runway for two years
Gained exclusive rights to premier... ► Artikel lesen | |
| SOLENO THERAPEUTICS | 64,95 | -4,27 % | Soleno Therapeutics: SVP verkauft Aktien im Wert von 265.156 US-Dollar | ||
| RAMSAY HEALTH CARE | 19,300 | -2,53 % | Goldman Sachs sets Ramsay Health Care stock at Neutral | ||
| SENSUS HEALTHCARE | 4,360 | +2,35 % | Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results | BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments... ► Artikel lesen |
XVIVO PERFUSION AB gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,900 (-3,38 %) liegt der Kurs bei 25,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XVIVO PERFUSION AB finden Sie auf Wallstreet Online.
